spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  naproxen 

 HSMN NewsFeed - 25 Sep 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF(R) Vial Access Needle ("VAN")
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 1 Jul 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 13 May 2021
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Oct 2018
Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 Aug 2018
Nuvo Pharmaceuticals(TM) Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Jan 2018
Pernix Announces Reorganization of Sales Force to Focus on Zohydro(R) ER with BeadTek(TM) and Silenor(R)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Mar 2016
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 May 2014
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Nov 2013
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Nov 2013
First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jul 2011
POZEN Announces Tomas S. Bocanegra, M.D. as Head of Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2011
Preliminary Injunction Ordered in POZEN Treximet Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Feb 2011
POZEN Announces Addition to Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2010
Mortality Data Presented for Patients Treated with Effient(R) Who Underwent Isolated Coronary Artery Bypass Surgery
Biopharmaceuticals Cardiology Surgery
 HSMN NewsFeed - 26 May 2010
Logical Therapeutics Secures $16.9M Series C Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 14 Apr 2010
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Jan 2010
New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 18 Nov 2009
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Sep 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2009
Sciele Pharma, a Shionogi Company, Terminates Agreement to Acquire Victory Pharma, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 May 2009
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Apr 2009
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2009
Victory Pharma Announces US$45 Million Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Mar 2009
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 Jan 2009
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Nov 2008
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2008
NicOx announces second naproxcinod pivotal phase 3 study (302) meets efficacy primary endpoints and supports non-detrimental blood pressure effect
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
NicOx announces blood pressure analysis from 301 phase 3 study for naproxcinod at EULAR
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2008
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Nov 2007
NicOx' naproxcinod phase 3 results presented at American College of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
New Clinical Study Shows Limbrel(TM) as Effective as Naproxen for Knee Osteoarthritis
BIopharmaceuticals
 HSMN NewsFeed - 1 Nov 2007
Pozen Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
POZEN Submits Response to Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
NicOx opens US headquarters in New Jersey
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Oct 2007
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
FDA Issues Second Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2007
Victory Pharma, Inc. Doubling U.S. Sales Force
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2007
Logical Therapeutics Inc. Raises US $30M Series B to Advance Drug Pipeline Targeting Inflammatory Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Victory Pharma, Inc. Completes the Acquisition of Naprelan(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 26 Mar 2007
Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial Operations
Biopharmaceuticals
 HSMN NewsFeed - 13 Mar 2007
Introducing New ALEVE(R) Liquid Gels
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2007
American Heart Association Scientific Statement: AHA Statement Recommends Doctors Change Approach to Prescribing Pain Relievers for Patients With or at Risk for Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Jan 2007
POZEN Names Gilda M. Thomas as Senior Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
Victory Pharma, Inc. Signs NAPRELAN(R) Agreement; US Field Sales Force to Expand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 13 Dec 2006
Pozen Expects to Submit Revised Response to Trexima(TM) (Sumatriptan/Naproxen Sodium) Approvable Letter by Year End
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Nov 2006
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Oct 2006
NicOx Naproxcinod Phase 3 OA Trial Meets Primary Endpoints and Shows Encouraging Blood Pressure Profile
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Consistent Efficacy and Tolerability of Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex(R) (Sumatriptan Succinate)
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
naproxen
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.